MUC20 expression marks the receptive phase of the human endometrium.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 20 01 2019
revised: 20 04 2019
accepted: 08 05 2019
pubmed: 15 9 2019
medline: 20 9 2020
entrez: 15 9 2019
Statut: ppublish

Résumé

How does mucin MUC20 expression change during the menstrual cycle in different cell types of human endometrium? Study involved examination of MUC20 expression in two previously published RNA-seq datasets in whole endometrial tissue (n = 10), sorted endometrial epithelial (n = 44) or stromal (n = 42) cell samples. RNA-Seq results were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in whole tissue (n = 10), sorted epithelial (n = 17) and stromal (n = 17) cell samples. MUC20 protein localization and expression were analysed in human endometrium by immunohistochemical analysis of intact endometrial tissue (n = 6) and also Western blot of cultured stromal and epithelial cells (n = 2). MUC20 is differentially expressed in the endometrium between the pre-receptive and receptive phases. We show that MUC20 is predominantly expressed by epithelial cells of the receptive endometrium, both at the mRNA (RNA-Seq, P = 0.005; qRT-PCR, P = 0.039) and protein levels (Western blot; immunohistochemistry, P = 0.029). Our results indicate MUC20 as a novel marker of mid-secretory endometrial biology. We propose a model of MUC20 function in the hepatocyte growth factor (HGF)-activated mesenchymal-epithelial transition (MET) receptor signalling specifically in the receptive phase. Further investigations should reveal the precise function of MUC20 in human endometrium and the possible connection between MUC20 and HGF-activated MET receptor signalling. MUC20 could potentially be included in the list of endometrial receptivity markers after further clinical validation.

Identifiants

pubmed: 31519421
pii: S1472-6483(19)30538-3
doi: 10.1016/j.rbmo.2019.05.004
pii:
doi:

Substances chimiques

HGF protein, human 0
MUC20 protein, human 0
Mucins 0
Hepatocyte Growth Factor 67256-21-7
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-736

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Artjom Stepanjuk (A)

Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia.

Mariann Koel (M)

Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia; Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia.

Martin Pook (M)

Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia.

Merli Saare (M)

Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu 50406, Estonia.

Kersti Jääger (K)

Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia.

Maire Peters (M)

Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu 50406, Estonia.

Kaarel Krjutškov (K)

Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia; Research Program of Molecular Neurology, Research Programs Unit, University of Helsinki, and Folkhälsan Institute of Genetics, Haartmaninkatu 8, Helsinki 00290, Finland.

Sulev Ingerpuu (S)

Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu 51010, Estonia.

Andres Salumets (A)

Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia; Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu 50406, Estonia; Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Haartmaninkatu 2, Helsinki 00014, Finland. Electronic address: andres.salumets@ccht.ee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH